DE3712767C2 - - Google Patents

Info

Publication number
DE3712767C2
DE3712767C2 DE3712767A DE3712767A DE3712767C2 DE 3712767 C2 DE3712767 C2 DE 3712767C2 DE 3712767 A DE3712767 A DE 3712767A DE 3712767 A DE3712767 A DE 3712767A DE 3712767 C2 DE3712767 C2 DE 3712767C2
Authority
DE
Germany
Prior art keywords
adjuvant
oil
detoxified
metabolizable
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3712767A
Other languages
German (de)
English (en)
Other versions
DE3712767A1 (de
Inventor
John L. Corvallis Mont. Us Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIBI IMMUNOCHEM RESEARCH Inc HAMILTON MONT US
Original Assignee
RIBI IMMUNOCHEM RESEARCH Inc HAMILTON MONT US
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIBI IMMUNOCHEM RESEARCH Inc HAMILTON MONT US filed Critical RIBI IMMUNOCHEM RESEARCH Inc HAMILTON MONT US
Publication of DE3712767A1 publication Critical patent/DE3712767A1/de
Application granted granted Critical
Publication of DE3712767C2 publication Critical patent/DE3712767C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE19873712767 1986-04-15 1987-04-15 Immunologisches adjuvans Granted DE3712767A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/852,120 US4806352A (en) 1986-04-15 1986-04-15 Immunological lipid emulsion adjuvant

Publications (2)

Publication Number Publication Date
DE3712767A1 DE3712767A1 (de) 1987-10-22
DE3712767C2 true DE3712767C2 (US08066781-20111129-C00013.png) 1991-06-27

Family

ID=25312542

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19873712767 Granted DE3712767A1 (de) 1986-04-15 1987-04-15 Immunologisches adjuvans

Country Status (9)

Country Link
US (1) US4806352A (US08066781-20111129-C00013.png)
JP (1) JPS6310736A (US08066781-20111129-C00013.png)
AU (1) AU574014B2 (US08066781-20111129-C00013.png)
CA (1) CA1300503C (US08066781-20111129-C00013.png)
DE (1) DE3712767A1 (US08066781-20111129-C00013.png)
ES (1) ES2005166A6 (US08066781-20111129-C00013.png)
FR (2) FR2598622B1 (US08066781-20111129-C00013.png)
GB (1) GB2189141B (US08066781-20111129-C00013.png)
IT (1) IT1205819B (US08066781-20111129-C00013.png)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
JPH0832637B2 (ja) * 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
WO1990003183A1 (en) * 1988-09-23 1990-04-05 University Of Southern California Immunotherapy vaccine for melanoma tumors
FI902821A0 (fi) * 1989-06-12 1990-06-06 Res Found Mental Hygiene Foerminskning av infektionsspridning medelst blodbehandlingsapparatur.
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU662146B2 (en) 1991-03-19 1995-08-24 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
ES2136620T3 (es) * 1991-04-19 1999-12-01 Lds Technologies Inc Formulaciones de microemulsiones convertibles.
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
PT812593E (pt) * 1993-03-23 2002-01-30 Smithkline Beecham Biolog Vacinas contendo monofosforil-lipido a 3-o-desacilado na sua composicao
ES2204919T3 (es) * 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
DE69908304T2 (de) * 1998-02-11 2004-02-19 Rtp Pharma Corp. Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US8415329B1 (en) 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
AU759641B2 (en) * 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
KR20010073232A (ko) 1998-11-20 2001-07-31 추후제출 분산성 인지질로 안정화된 마이크로입자
NZ514883A (en) 1999-04-09 2004-03-26 Upjohn Co Anti-bacterial vaccine compositions
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
MXPA02008748A (es) 2000-03-17 2003-02-24 Upjohn Co Materiales y metodos para vacuna antisalmonella.
AU2001251370A1 (en) 2000-04-06 2001-10-23 Pharmacia And Upjohn Company Antimicrobial methods and materials
CA2407027C (en) 2000-04-20 2011-02-15 Rtp Pharma Inc. Improved water-insoluble drug particle process
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
EP1313451B1 (en) 2000-08-31 2009-03-11 Jagotec AG Milled particles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
AU2001255515A1 (en) * 2000-09-20 2002-04-02 Skyepharma Canada Inc. Stabilised fibrate microparticles
TWI288000B (en) * 2001-02-22 2007-10-11 Rtp Pharma Inc Fibrate-statin combinations with reduced fed-fasted effects
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
CA2513655C (en) 2003-01-21 2011-11-22 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
ATE539079T1 (de) * 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
EP2007765B1 (en) * 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
ES2588705T3 (es) * 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
ES2524699T3 (es) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
EP2529641B1 (en) 2010-01-29 2015-11-11 Kabushiki Kaisha Mikimoto Clasp for accessory
JP6030052B2 (ja) 2010-05-14 2016-11-24 バクスアルタ インコーポレイテッド Ｏｓｐａキメラおよびそのワクチンでの使用法
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
JP2014500267A (ja) 2010-12-08 2014-01-09 ネオヴァクス 強力に不活性化されているがなお高い免疫原性を示すワクチンおよびその製造方法
AU2012238643B2 (en) 2011-04-07 2017-04-13 Neovacs Method for treating IFNalpha related conditions
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
US9023367B2 (en) 2012-07-27 2015-05-05 Baxter International Inc. Compositions comprising chimeric OSPA molecules and methods of use thereof
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
EA201790558A1 (ru) 2014-10-15 2017-08-31 Ксенотера Композиция с пониженной иммуногенностью
US20210228713A1 (en) 2018-06-04 2021-07-29 Apros Therapeutics, Inc. Tlr7 peptide conjugates
JP2021535080A (ja) 2018-07-02 2021-12-16 アユヴィス リサーチ インク.Ayuvis Research, Inc. 新規免疫調節小分子
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
GB202009411D0 (en) 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
CN112807426A (zh) * 2021-01-26 2021-05-18 郭志文 一种基于动物疫苗的聚合物佐剂、制备方法及其应用
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
WO2023036814A1 (en) 2021-09-07 2023-03-16 Universite De Tours Coronavirus fusion protein
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
FR2160326B1 (US08066781-20111129-C00013.png) * 1971-11-19 1975-02-07 Anvar
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPH077201B2 (ja) * 1985-10-19 1995-01-30 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法

Also Published As

Publication number Publication date
FR2596990A1 (fr) 1987-10-16
GB2189141A (en) 1987-10-21
FR2598622A1 (fr) 1987-11-20
US4806352A (en) 1989-02-21
IT1205819B (it) 1989-03-31
GB2189141B (en) 1990-07-25
JPS6310736A (ja) 1988-01-18
FR2596990B1 (fr) 1990-12-07
CA1300503C (en) 1992-05-12
AU7156687A (en) 1987-10-22
IT8747855A0 (it) 1987-04-15
ES2005166A6 (es) 1989-03-01
DE3712767A1 (de) 1987-10-22
GB8709023D0 (en) 1987-05-20
AU574014B2 (en) 1988-06-23
JPH041728B2 (US08066781-20111129-C00013.png) 1992-01-14
FR2598622B1 (fr) 1990-05-11

Similar Documents

Publication Publication Date Title
DE3712767C2 (US08066781-20111129-C00013.png)
DE3712768C2 (US08066781-20111129-C00013.png)
DE69928763T2 (de) Adjuvanzien zur Verwendung in Impfstoffen
DE69937343T2 (de) Adjuvanszusammensetzung und methoden zu deren verwendung
DE69826842T2 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
DE3787663T2 (de) Impfstofformulierung.
DE69623072T3 (de) Impfstoffzusammensetzung für Säugetiere enthaltend Squalen oder Squalan, Phospholipid und ein Tensid als Adjuvans
DE2528411C2 (US08066781-20111129-C00013.png)
DE69004094T2 (de) Mehrphasige injizierbare emulsionen.
DE69533693T2 (de) Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
DE69636889T2 (de) Öladjuvierter Impfstoff und Verfahren zu seiner Herstellung
DE4499552C1 (de) Adjuvans für Antigene, Verfahren zur Herstellung und Verwendung
DE69634024T2 (de) Adjuvans für vitale Impfstoffe
DE3806565C2 (US08066781-20111129-C00013.png)
DE60002650T2 (de) Öladjuvierter Impfstoff
DE2603321A1 (de) Emulsion auf der grundlage eines stoffwechselfaehigen pflanzlichen oels und wasser
DE3604109A1 (de) Impfstoff-system
DE3889521T2 (de) Impfstoff-Adjuvans.
DE60019726T2 (de) Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans
DE2547105A1 (de) N-acetyl-muramyl-l-alanyl-d-isoglutamin enthaltende oelfreie adjuvanzien
DE2643641A1 (de) Antigene praeparate und verfahren zu ihrer herstellung
DE60031243T2 (de) Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
DE1467750C3 (de) Verfahren zum Gewinnen von wertvollen Bestandteilen aus Pollen
DE69827837T2 (de) Antigenvektoren bestehend aus multilamellarförmigen bläschen
EP0343548B1 (de) Antigenlösung ethaltend ein Polyalphaolefin (PAO), Verfahren ihrer Herstellung und die Verwendung von PAO als Adjuvans

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition